We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.
Pure Biologics has bet on a stable and balanced development in all business areas key for its operations – R&D project portfolios, scientific and business expertise, infrastructure and networking with big biotechnology and pharmaceutical players. Our plans envisage achieving financial independence and demonstrating revenue as quickly as possible, allowing us to start working on our next, advanced ideas. To this end, we focus on investments in our own, currently ongoing R&D projects, in order to efficiently commercialize their results.
1
Portfolio of therapeutic solutions
in the area of innovative biological drugs and medical devices. Research programs focus on therapeutic molecules being first-in-class in the immuno-oncology and neurological rare diseases segments. Our portfolio is based on proprietary technology platforms for antibody and aptamer selections.
2
Commercial partnership
with pharmaceutical and biotechnological companies. It is based on acquired know-how, technology assets and qualified personnel. Partnerships focus on new solutions to broaden scientific competences and on building and strengthening business relationships.
3
Financing sources
for the development strategy includes internal funds, funds acquired from commercial partnerships, European Union and Polish grants for research & development projects, and financial resources acquired from licensing out developed therapeutic molecules. In the long-term, project commercialization will enable financial independence and acquisition of resources for future projects.
4
Developmental investments
will focus on using financial means primarily for R&D projects. Steering several projects in parallel requires substantial expenditures. Because of this, the Company intends to invest in the further development of these projects in order to build a balanced portfolio, to minimize risk and to achieve revenue from their commercialization.
Investors & media
Pure Biologics is the first entity in Poland to focus on development of completely new, not generic or biosimilar, biological drugs based on antibodies and therapeutic aptamers. This is a challenge that is currently a leading trend in the global pharmaceutical industry with potential to yield at least a dozen-fold the return on investment.